Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product

• US 5,641,750 A
• Filed: 11/29/1995
• Issued: 06/24/1997
• Est. Priority Date: 11/29/1995
• Status: Expired due to Term

• Current Assignee: Amgen Inc.
• Original Assignee: Amgen Inc.
• Inventors: Louis, Jean-Claude
• Primary Examiner(s): Schain, Howard E.
• Assistant Examiner(s): TOUZEAU, LYNN
• Application Number:
  US08/564,833
• Time in Patent Office: 573 Days
• Field of Search: 514/12, 435/69.1, 435/69.4
• US Class Current: 424/423
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/185 Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

The present invention relates generally to methods for treating injury or degeneration of retinal neurons, and in particular photoreceptors, by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates specifically to methods for treating retinal conditions or diseases in which vision is lost such as retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathies, photic retinopathies, surgery-induced retinopathies, viral retinopathies, ischemic retinopathies, retinal detachment and traumatic retinopathy.

Claims

1. A method for treating injury or degeneration of photoreceptors, comprising administering to a subject suffering from such photoreceptor injury or degeneration a therapeutically effective amount of a glial cell line-derived neurotrophic factor (GDNF) protein product.

2. The method of claim 1 wherein the injury or degeneration of the photoreceptors is associated with retinitis pigmentosa, Bardet-Biedl syndrome, Bassen-Kornzweig syndrome (abetalipoproteinemia), Best disease (vitelliform dystrophy), choroidemia, gyrate atrophy, congenital amaurosis, Refsum syndrome, Stargardt disease and Usher syndrome, age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathies, photic retinopathies, surgery-induced retinopathies, vital retinopathies, ischemic retinopathies, retinal detachment or traumatic retinopathy.

3. The method of claim 1 wherein the GDNF protein product comprises the amino acid sequence set forth in SEQ ID NO:

1 or a variant, or a derivative thereof.

4. The method of claim 3 wherein the GDNF protein product has the amino acid sequence set forth in SEQ ID NO:

1.

5. The method of claim 3 wherein the GDNF protein product is [Met^-1 ]GDNF.

6. The method of claim 1 wherein the GDNF protein product comprises GDNF attached to a water soluble polymer.

7. The method of claim 6 wherein the water soluble polymer is polyethylene glycol.

8. The method of claim 1 wherein the GDNF protein product comprises a truncated GDNF protein product.

9. The method of claim 1 wherein the GDNF protein product is administered at a dose between about 0.001 mg/day and 10 mg/day.

10. The method of claim 9 wherein the GDNF protein product is administered at a dose between about 0.1 mg/day and 0.5 mg/day.

11. The method of claim 1 wherein the GDNF protein product is administered as a sustained-release pharmaceutical composition.

12. The method of claim 1 wherein the GDNF protein product is administered as a topical, oral or parenteral pharmaceutical composition.

13. The method of claim 1 wherein the GDNF protein product is administered by cell therapy or gene therapy means wherein cells have been modified to produce and secrete the GDNF protein product.

14. The method of claim 13 wherein the cells have been modified ex vivo.

15. The method of claim 13 wherein the cells have been modified in vivo.

16. The method of claim 1 further comprising administering to the patient an effective amount of a second therapeutic agent for treating retinal disease.

17. The method of claim 16 wherein the second therapeutic agent is selected from the group consisting of brain derived neurotrophic factor, neurotrophin-3, neurotrophin-4/5, neurotrophin-6, insulin-like growth factor, ciliary neurotrophic factor, acidic and basic fibroblast growth factors, fibroblast growth factor-5, transforming growth factor-β

, and cocaine-amphetamine regulated transcript.

18. The method of claim 1 wherein the GDNF protein product is administered by a delivery means selected from the group consisting of ocular inserts, ocular injection or ocular implants.

19. A method for providing photoreceptor cells for implantation comprising culturing dissociated photoreceptor cells in the presence of a glial cell line-derived neurotrophic factor (GDNF) protein product.